TBPH · Theravance Biopharma, Inc.
$16.86
+0.00 (+0.00%)
At close · Jul 24
Market Cap
$869.18M
Shares
51.55M
Theravance Biopharma, Inc. Earnings Call Transcripts
Every quarterly earnings call for Theravance Biopharma, Inc. (TBPH) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼7.4%
$13.20M
−$25.95M
'22 Q1
22-05-05
▼14.4%
$11.05M
−$8.19M
'22 Q2
22-08-04
▼5.6%
$12.45M
$916.63M
'22 Q3
22-11-07
▼2%
$14.65M
−$10.36M
'22 Q4
23-01-09
▼21.1%
$10.42M
−$22.09M
'23 Q1
23-05-08
▲24.4%
$13.75M
−$15.64M
'23 Q2
23-08-07
▲26%
$15.69M
−$8.95M
'23 Q3
23-11-07
▲19.9%
$17.57M
−$8.51M
'23 Q4
24-02-26
▲39.2%
$14.50M
−$11.66M
'24 Q1
24-05-13
▲3.7%
$14.26M
−$16.53M
'24 Q2
24-08-05
▲7.5%
$16.87M
−$12.70M
'24 Q3
24-11-12
▲6.8%
$18.75M
−$15.53M
'24 Q4
25-02-26
▲6.1%
$15.39M
−$13.58M
'25 Q1
25-05-08
▲83.7%
$26.20M
$54.84M
'25 Q2
25-08-12
▲18.5%
$19.99M
$3.62M
'25 Q3
25-11-10
LATEST
▲15%
$17.70M
−$4.93M
'26 Q1
26-05-07
Earnings call
FY26 · Q1
2026-05-07
Theravance Biopharma, Inc. Q1 FY2026 Earnings Call
Revenue
$17.70M
▲ 15% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q3
2025-11-10
Theravance Biopharma, Inc. Q3 FY2025 Earnings Call
Confident tone
Ampreloxetine / Cyprus Phase III
YUPELRI commercial performance
Milestone payments from Viatris/GSK
Revenue
$19.99M
▲ 18.5% YoY Diluted EPS
$0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Theravance Biopharma, Inc. Q2 FY2025 Earnings Call
Confident tone
Ampreloxetine CYPRESS Phase III
YUPELRI commercial performance
YUPELRI China approval
Revenue
$26.20M
▲ 83.7% YoY Diluted EPS
$1.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Theravance Biopharma, Inc. Q1 FY2025 Earnings Call
Confident tone
Ampreloxetine / CYPRESS study
YUPELRI commercial performance
Trelegy royalties and milestones
Revenue
$15.39M
▲ 6.1% YoY Diluted EPS
$-0.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Theravance Biopharma, Inc. Q4 FY2024 Earnings Call
Confident tone
Ampreloxetine CYPRESS study and NDA preparation
YUPELRI commercial performance
TRELEGY milestones and royalties
Revenue
$18.75M
▲ 6.8% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Theravance Biopharma, Inc. Q3 FY2024 Earnings Call
Confident tone
Hospital and community share growth
YUPELRI commercial performance
China expansion opportunity
Revenue
$16.87M
▲ 7.5% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Theravance Biopharma, Inc. Q2 FY2024 Earnings Call
Balanced tone
YUPELRI net sales and pricing
CYPRESS study timeline delay
Financial position and cash runway
Revenue
$14.26M
▲ 3.7% YoY Diluted EPS
$-0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Theravance Biopharma, Inc. Q1 FY2024 Earnings Call
Confident tone
YUPELRI commercial performance
Ampreloxetine CYPRESS trial
TRELEGY royalties and milestones
Revenue
$14.50M
▲ 39.2% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Theravance Biopharma, Inc. Q4 FY2023 Earnings Call
Confident tone
YUPELRI commercial growth
Ampreloxetine CYPRESS study
China market opportunity for YUPELRI
Revenue
$17.57M
▲ 19.9% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Theravance Biopharma, Inc. Q3 FY2023 Earnings Call
Revenue
$15.69M
▲ 26% YoY Diluted EPS
$-0.17
▼ 101.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Theravance Biopharma, Inc. Q2 FY2023 Earnings Call
Revenue
$13.75M
▲ 24.4% YoY Diluted EPS
$-0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Theravance Biopharma, Inc. Q1 FY2023 Earnings Call
Revenue
$10.42M
▼ 21.1% YoY Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Theravance Biopharma, Inc. Q4 FY2022 Earnings Call
Revenue
$14.65M
▼ 2% YoY Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Theravance Biopharma, Inc. Q3 FY2022 Earnings Call
Revenue
$12.45M
▼ 5.6% YoY Diluted EPS
$12.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Theravance Biopharma, Inc. Q2 FY2022 Earnings Call
Revenue
$11.05M
▼ 14.4% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Theravance Biopharma, Inc. Q1 FY2022 Earnings Call
Revenue
$13.20M
▼ 7.4% YoY Diluted EPS
$-0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Theravance Biopharma, Inc. Q4 FY2021 Earnings Call
Revenue
$14.95M
▼ 20.2% YoY Diluted EPS
$-0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Theravance Biopharma, Inc. Q3 FY2021 Earnings Call
Revenue
$13.19M
▼ 27.7% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Theravance Biopharma, Inc. Q2 FY2021 Earnings Call
Revenue
$12.91M
▼ 14% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Theravance Biopharma, Inc. Q1 FY2021 Earnings Call
Revenue
$14.26M
▼ 28.2% YoY Diluted EPS
$-1.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Theravance Biopharma, Inc. Q4 FY2020 Earnings Call
Revenue
$18.73M
▼ 36.5% YoY Diluted EPS
$-0.92
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Theravance Biopharma, Inc. Q3 FY2020 Earnings Call
Revenue
$18.26M
▲ 46.9% YoY Diluted EPS
$-1.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Theravance Biopharma, Inc. Q2 FY2020 Earnings Call
Revenue
$15.01M
▼ 42.6% YoY Diluted EPS
$-1.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Theravance Biopharma, Inc. Q1 FY2020 Earnings Call
Revenue
$19.86M
▲ 272.1% YoY Diluted EPS
$-1.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-24
Theravance Biopharma, Inc. Q4 FY2019 Earnings Call
Revenue
$29.50M
▲ 87.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–25 of 25 earnings calls
Key facts
CIK
1583107
CUSIP
G8807B106
13F (30d)
21 filings
21 filers
Visit website
Investor relations